Search results for "PATHOGENESIS"

showing 10 items of 761 documents

Reconstitution of CD8 T cells is essential for the prevention of multiple-organ cytomegalovirus histopathology after bone marrow transplantation.

1998

Cytomegalovirus (CMV) infection in the period of temporary immunodeficiency after haematoablative treatment and bone marrow transplantation (BMT) is associated with a risk of graft failure and multiple-organ CMV disease. The efficacy of immune system reconstitution is decisive for the prevention of CMV pathogenesis after BMT. Previous data in murine model systems have documented a redundancy in the immune effector mechanisms controlling CMV. CD8 T cells proved to be relevant but not irreplaceable as antiviral effectors. Specifically, in a state of long-term in vivo depletion of the CD8 T-cell subset, CD4 T cells were educed to become deputy effectors controlling CMV by a mechanism involving…

CD4-Positive T-LymphocytesCongenital cytomegalovirus infectionCytomegalovirusGraft vs Host DiseaseCD8-Positive T-LymphocytesBiologyVirus ReplicationLymphocyte DepletionPathogenesisMiceImmune systemRisk FactorsIn vivoVirologymedicineAnimalsHumansCytotoxic T cellImmunodeficiencyBone Marrow TransplantationMice Inbred BALB CEffectorvirus diseasesmedicine.diseaseVirologyDisease Models AnimalTransplantation IsogeneicCytomegalovirus InfectionsImmunologyCD8Journal of General Virology
researchProduct

Is TNF-α really involved in giant cell arteritis pathogenesis?

2013

Giant cell arteritis (GCA) is the most frequent vasculitis in people >50 years, and glucocorticoids (GC) remain the cornerstone of the treatment. However, this long-term treatment is responsible for numerous GC-related complications.1 Thus, reliable GC-sparing drugs need to be explored. Seror et al 2 have recently reported the inefficacy of adalimumab, a humanised anti-TNF-α therapy, as a GC-sparing drug in the treatment of GCA. These clinical results contrast with previous studies reporting a production of TNF-α by giant cells and macrophages in GCA lesions.3 However, recent advance in the knowledge of GCA pathogenesis have shown that macrophages and giant cells are not involved in the fir…

CD4-Positive T-LymphocytesMaleImmunologyGiant Cell ArteritisGeneral Biochemistry Genetics and Molecular BiologyPathogenesisRheumatologyimmune system diseasesAdalimumabImmunology and AllergyMedicineHumanscardiovascular diseasesskin and connective tissue diseasesAgedAged 80 and overbusiness.industryTumor Necrosis Factor-alphaMiddle Agedmedicine.diseaseGiant cell arteritisGiant cellImmunologycardiovascular systemTumor necrosis factor alphaFemalebusinessVasculitismedicine.drugAnnals of the rheumatic diseases
researchProduct

Immunological pattern in patients with 21-hydroxylase deficiency.

1994

The aim of this work was to perform an immunological study in six patients with 21 hydroxylase deficiency in mild form (M210HD) and in 2 patients with 21-hydroxylase deficiency in classical form (C210HD) and in their parents, in whom a previous HLA,C4,Bf typing demonstrated high prevalence of DR5 and phenotypic absence of fraction C4B of complement (C4BQO). This study contains the evaluation of C3, IgA, IgG, IgM levels, anticardiolipin antibodies (IgG and IgM) and circulating immunocomplexes. A study of lymphocyte subsets was also performed. Among M210HD 1 patient showed presence of anticardiolipin antibodies both IgM and IgG; this patient had shown antinuclear antibodies in a previous stud…

CD4-Positive T-LymphocytesMalemedicine.medical_specialtyAnti-nuclear antibodyAdolescentEndocrinology Diabetes and MetabolismHuman leukocyte antigenImmunogeneticsBiologymedicine.disease_causeT-Lymphocytes RegulatoryAutoimmunityPathogenesisEndocrinologyImmune systemImmunityInternal medicinemedicineHumansFamily HealthAdrenal Hyperplasia CongenitalImmunityT-Lymphocytes Helper-InducerEndocrinologyImmunoglobulin MAntibodies AnticardiolipinImmunoglobulin GImmunologybiology.proteinFemaleAntibodyJournal of endocrinological investigation
researchProduct

Human Papillomavirus Type 33 E7 Peptides Presented by HLA-DR*0402 to Tumor-Infiltrating T Cells in Cervical Cancer

2000

ABSTRACTSeveral characteristics make human papillomavirus (HPV) amenable to vaccination. Anti-HPV-directed vaccines are based on the observation that HPV E6 and E7 oncoproteins are constitutively expressed in HPV-positive cervical cancer and may serve as tumor rejection antigens. Five HPV types (16, 18, 31, 33, and 45) account for 80% of cervical cancer. Until now, the type of immune response capable of mediating an effective antitumor response has not been defined. In order to define the anticancer-directed immune response in situ, we characterized CD4+and CD8+sorted T cells from peripheral blood lymphocytes, freshly harvested tumor tissue, and tumor-infiltrating lymphocytes (TIL) from a p…

CD4-Positive T-LymphocytesT-LymphocytesMolecular Sequence DataImmunologyAntigen presentationReceptors Antigen T-CellUterine Cervical NeoplasmsCD8-Positive T-LymphocytesMajor histocompatibility complexMicrobiologyEpitopeEpitopesInterferon-gammaLymphocytes Tumor-InfiltratingImmune systemAntigenVirologymedicineHumansAmino Acid SequencePapillomaviridaePapillomaviridaeCervical cancerAntigen PresentationbiologyHLA-DR AntigensOncogene Proteins ViralFlow Cytometrymedicine.diseasebiology.organism_classificationImmunohistochemistryPeptide FragmentsInsect ScienceImmunologybiology.proteinCancer researchPathogenesis and ImmunityFemaleCD8Journal of Virology
researchProduct

Translating Inflammatory Bowel Disease Research into Clinical Medicine

2009

Recent studies have provided important insights into the pathogenesis of inflammatory bowel disease (IBD). The development of new therapeutic agents has been triggered by basic research and studies in mouse models of IBD. It is expected that improved translational research will lead to optimized therapy and new individualized treatment options.

CD4-Positive T-Lymphocytesmedicine.medical_specialtyImmunologyAnti-Inflammatory AgentsIndividualized treatmentTranslational researchGastroenterologyInflammatory bowel diseasePathogenesisBasic researchInternal medicineDrug DiscoverymedicineAnimalsHumansImmunology and AllergyIntensive care medicineMononuclear Phagocyte Systembusiness.industryInterleukinsmedicine.diseaseInflammatory Bowel Diseasesdigestive system diseasesDisease Models AnimalInfectious DiseasesbusinessImmunity
researchProduct

Allergic contact dermatitis: understanding the immune response and potential for targeted therapy using cytokines.

1997

Allergic contact dermatitis is the most common job-related disease of the western world. The only available treatments are avoidance of contact with the allergen and the use of potent corticosteroids. Recently, the role of cytokines in the pathogenesis of this disease has been studied and, besides defining the key molecules and basic cellular immune responses responsible for disease development, these studies might help to develop new therapeutic strategies to target cytokines and thereby try to alter or abrogate ongoing immune reactions.

CD4-Positive T-Lymphocytesmedicine.medical_treatmentT-LymphocytesDiseaseCD8-Positive T-Lymphocytesmedicine.disease_causeLymphocyte ActivationTargeted therapyPathogenesisMiceImmune systemAllergenGeneticsmedicineAnimalsHumansRNA AntisenseAllergic contact dermatitisbusiness.industryDendritic CellsGenetic Therapymedicine.diseaseLangerhans CellsImmunologyDermatitis Allergic ContactMolecular MedicineCytokinesImmune reactionbusinessMolecular medicine today
researchProduct

Effects of cigarette smoke in tissue-engineered human bronchial mucosa: new insights on COPD pathogenesis.

2012

COPD pathogenesis.smokeSettore BIO/16 - Anatomia Umanahuman bronchial mucosatissue-engineered
researchProduct

Cachexia: a therapeutic approach beyond cytokine antagonism

2002

Cachexia is seen in a number of chronic diseases, and it is always associated with a poor prognosis. Irrespective of etiology, the development of cachexia appears to share a common pathophysiological pathway. This includes induction of proteasome-dependent myofibril-degradation, which is thought to be secondary to stimulation by enhanced levels of pro-inflammatory cytokines. Elevation of tumor necrosis factor-alpha (TNFalpha) and other plasma cytokines has been demonstrated in many conditions associated with cachexia. Despite improved pathophysiological understanding, a specific treatment for cachexia has not yet been established. Whilst direct TNFalpha antagonism has therapeutic appeal, th…

CachexiaTumor Necrosis Factor-alphabusiness.industrymedicine.medical_treatmentNF-kappa BImmunosuppressionNF-κBmedicine.diseaseCachexiaTranscription Factor AP-1PathogenesisTherapeutic approachchemistry.chemical_compoundTreatment OutcomeCytokinechemistryImmunologyCytokinesHumansMedicineTumor necrosis factor alphaCardiology and Cardiovascular MedicineAntagonismbusinessImmunosuppressive AgentsInternational Journal of Cardiology
researchProduct

Lysosomal alterations in heart and liver of mice treated with doxorubicin.

1985

This study was carried out to evaluate the influence of long-term treatment with doxorubicin (DXR) (4mg/kg IV for 5 weeks) on heart and liver lysosomes of mice. We evaluated the variations in both total and "sedimentable" enzyme activity of cathepsin D, which is the major endopeptidase of myocites and probably involved in physiologic and pathologic degradation of actomyosin and mitochondria, and that of acid phosphatase, which is more prominent in interstitial cells. Our results show that marked changes occur in both total and sedimentable enzyme activity of cathepsin D in the heart of treated animals and to a lesser extent in the liver. In contrast, no modification of either total or sedim…

Cancer Researchmedicine.medical_specialtyAcid Phosphatasecardiotoxicity lisosomal enzymesCathepsin DMice Inbred StrainsToxicologyCathepsin DPathogenesisAdriamycinMiceLysosomeInternal medicinemedicineAnimalsPharmacology (medical)DoxorubicinPharmacologyCardiotoxicitybiologyMyocardiumAcid phosphataseHeartEnzyme assayEndocrinologymedicine.anatomical_structureOncologyLiverDoxorubicinToxicitybiology.proteinFemaleLysosomesmedicine.drugCancer chemotherapy and pharmacology
researchProduct

Clinical and Molecular-Based Approach in the Evaluation of Hepatocellular Carcinoma Recurrence after Radical Liver Resection

2021

Background: Hepatic resection remains the treatment of choice for patients with early-stage HCC with preserved liver function. Unfortunately, however, the majority of patients develop tumor recurrence. While several clinical factors were found to be associated with tumor recurrence, HCC pathogenesis is a complex process of accumulation of somatic genomic alterations, which leads to a huge molecular heterogeneity that has not been completely understood. The aim of this study is to complement potentially predictive clinical and pathological factors with next-generation sequencing genomic profiling and loss of heterozygosity analysis. Methods: 124 HCC patients, who underwent a primary hepatic …

Cancer Researchmedicine.medical_specialtyHepatitis C virusSubgroup analysisLower riskmedicine.disease_causelcsh:RC254-282GastroenterologyArticlePathogenesisLoss of heterozygositynext-generation sequencing.03 medical and health sciences0302 clinical medicineInternal medicineMedicinePTENHCCHCC recurrencebiologybusiness.industrylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseOncology030220 oncology & carcinogenesisHepatocellular carcinomaliver resectionbiology.proteinnext-generation sequencingloss of heterozygosity030211 gastroenterology & hepatologyLiver functionbusinessCancers
researchProduct